Medical Devices Startups
6,434 companies tagged Medical Devices, with their investors and founders.
Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
2 investors
Zeto develops improved electroencephalography technology for diagnosing epilepsy and other neurological conditions. The company serves physicians and medical institutions seeking advanced EEG diagnostic tools.
2 investors
ZYMEDI is a drug discovery company that partners through R&D joint ventures, strategic investments, and in-licensing arrangements. It works with collaborators across the pharmaceutical and biotechnology sector.
2 investors
Surginex develops lipid nanoparticle and RNA platforms for therapeutic applications, serving pharmaceutical and biotech companies in drug development.
2 investors
Exosystems develops AI-based digital biomarkers for the assessment, monitoring, and treatment of neuromuscular and musculoskeletal disorders, supporting diagnosis, severity assessment, and disease progression tracking for conditions such as stroke, Parkinson's, ALS, SMA, sarcopenia, and myasthenia gravis. Its technology aims to provide faster, non-invasive, and reproducible quantitative neuromuscular evaluations for clinical and healthcare settings.
2 investors
L&K Biomed develops spinal medical devices and related surgical products. The company focuses on research and development of orthopedic and spine healthcare technology.
2 investors
Airato is a Japanese medical device startup developing AI-powered software for radiation therapy planning and delivery. The company aims to improve cancer treatment outcomes and quality of life for patients through advanced radiation oncology technology.
2 investors
AccuRna develops drug delivery systems for nucleic acid therapeutics, including antisense oligonucleotides, siRNA, miRNA, and mRNA-based treatments. The company focuses on enabling the development of novel medicines for refractory diseases with no current cure.
2 investors
IMMUNOSENS manufactures in vitro diagnostic pharmaceuticals and third-class medical devices for clinical diagnostic purposes. The company holds regulatory approvals from Japanese authorities for these medical products.
2 investors
AI Silk manufactures and sells lead skins (electrodes) and related electrode application products. The company serves medical and industrial sectors requiring specialized electrode technology.
2 investors
Orizuru Therapeutics develops cellular therapy products and regenerative medicine treatments utilizing iPS cell-related technology. The company supports drug discovery research and establishes regenerative medicine research infrastructure for the Japanese healthcare and biotechnology sectors.
2 investors
Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
2 investors
Kringle Pharma develops and manufactures HGF protein-based pharmaceuticals for treating conditions including spinal cord injury, ALS, and vocal cord scarring. The company is a spin-out of Osaka University and Keio University focused on drug development in the biotech sector.
2 investors
Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection. It initially targets patients with congenital tooth agenesis (a rare genetic condition) and ultimately aims to treat tooth loss from decay or periodontal disease.
2 investors
Hynts Technology develops nanotechnology-based products for cellular delivery and extraction applications. The company offers nanostructured membrane stamps, microscope-mounted stamping systems, and cell processing services for research and biotech applications.
2 investors
FIMECS, Inc. is a Japanese drug discovery company researching and developing new pharmaceuticals based on targeted protein degradation mechanisms.
2 investors
BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
2 investors
AFI manufactures rapid microbial detection systems using flow cytometry and solid-phase cytometry technologies for quality control in pharmaceuticals, clinical diagnostics, cosmetics, food and beverage, and environmental testing.
2 investors
EXORPHIA develops extracellular vesicle (EV) technology for assisted reproductive medicine, focusing on cell-free IVF culture medium additives to improve embryo development and fertilization success rates. The company targets fertility clinics and academic institutions in reproductive medicine.
2 investors
iXgene develops regenerative medicine therapies using genome-edited induced pluripotent stem cells (iPSCs) to treat conditions including glioblastoma and traumatic brain injury. The company focuses on gene and cell therapies derived from genetically engineered stem cells.
2 investors
Lifescapes develops brain-machine interface (BMI) technologies, including medical-grade and rehabilitation-focused devices for hand and finger control applications.
2 investors
Luxonus develops photoacoustic (optical ultrasound) 3D imaging devices and services for visualizing blood and lymphatic vessels, building on technology from Japan's Cabinet Office ImPACT program. The company designs, manufactures, and sells medical imaging equipment based on photoacoustic technology, and is based in Japan.
2 investors
Mitate Zepto Technica develops specialized semiconductor and computing hardware for genome analysis, including custom processors, accelerator boards, and supercomputers that perform genomic sequencing at significantly higher speeds and lower costs than conventional systems.
2 investors
Smart119 develops ICT-based technology aimed at solving problems in medical and emergency care settings to help treat more patients. The company applies information and communications technology to deliver advanced medical care in Japan.
2 investors